The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Rachiglio, Anna Maria, Fenizia, Francesca, Piccirillo, Maria Carmela, Galetta, Domenico, Crinò, Lucio, Vincenzi, Bruno, Barletta, Emiddio, Pinto, Carmine, Ferraù, Francesco, Lambiase, Matilde, Montanino, Agnese, Roma, Cristin, Ludovini, Vienna, Montagna, Elisabetta Sara, De Luca, Antonella, Rocco, Gaetano, Botti, Gerardo, Perrone, Francesco, Morabito, Alessandro, Normanno, Nicola
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468673/
https://ncbi.nlm.nih.gov/pubmed/30857358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados